市場調查報告書

全球尖端醫療醫藥品(ATMP)市場:治療類型,各地區 - 市場規模,佔有率,趨勢,各市場區隔預測(2020年∼2026年)

Advanced Therapy Medicinal Products Market Size, Share & Trends Analysis Report By Therapy Type (Cell, CAR-T, Gene Therapy, Stem Cell, Non-stem Cell), By Region, And Segment Forecasts, 2020 - 2026

出版商 Grand View Research, Inc. 商品編碼 927115
出版日期 內容資訊 英文 140 Pages
商品交期: 2-3個工作天內
價格
全球尖端醫療醫藥品(ATMP)市場:治療類型,各地區 - 市場規模,佔有率,趨勢,各市場區隔預測(2020年∼2026年) Advanced Therapy Medicinal Products Market Size, Share & Trends Analysis Report By Therapy Type (Cell, CAR-T, Gene Therapy, Stem Cell, Non-stem Cell), By Region, And Segment Forecasts, 2020 - 2026
出版日期: 2020年02月28日內容資訊: 英文 140 Pages
簡介

全球尖端醫療醫藥品(ATMP)市場在預測期間內預計將以17.4%的年複合成長率,2026年達到96億美元的規模。尖端醫療醫藥品(ATMP)的使用,確實證明有助於病情嚴重的患者的長期生活品質和對健康狀態的改善。這尤其適合很少或沒有替代療法的疾病病,這些新的治療方法,提供傳統形態的疾病治療所沒有的變革性優點,促進該市場的成長。

本報告提供全球尖端醫療醫藥品(ATMP)市場的相關調查,市場機會和趨勢,各治療類型、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 摘要整理

  • 市場預測
  • 競爭環境
  • 市場區隔預測
  • 市場概述

第2章 調查方法

  • 資訊採購
  • 資訊、資料分析
  • 市場定式化與檢驗
  • 市場範圍、定義
  • 市場模式

第3章 市場變數,趨勢,及規模

  • 先進療法醫藥品(ATMP)市場力學
  • 法規預測:各地區
  • 付款、定價模式
  • 專利預測
  • 交易,資金籌措,聯盟、合作
  • 開發平台分析
  • 先進療法醫藥品(ATMP)市場:各SWOT分析,要素(政治,法律,經濟,及技術)
  • 產業分析:波特的五力分析

第4章 市場分析:各治療類型

  • 市場趨勢分析
  • 細胞療法
    • 幹細胞療法
    • 非幹細胞療法
  • 基因治療
  • CAR-T療法
  • 組織工程產品

第5章 市場分析:各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第6章 競爭情形

  • 策略架構
  • 主要市場參與企業的分類
  • 企業簡介
目錄
Product Code: GVR-3-68038-855-8

The global advanced therapy medicinal products market size is expected to reach USD 9.6 billion by 2026, expanding at a CAGR of 17.4% over the forecast period, according to a new report published by Grand View Research, Inc. The use of advanced therapy medicinal products (ATMPs) is well-proven for the improvement in the quality of life and health status in the long run for patients suffering from life-threatening conditions. This is particularly for diseases with few or no alternative treatment options. These novel treatment modes deliver transformative advantages not offered by conventional forms of disease treatment, thereby driving the ATMP market.

In the current scenario, ATMPs are expensive for patients as well as health insurance schemes. Growing competition to gain revenue share could help reduce prices and improve the affordability, along with the acceptance of these products as mainstream medicine. Furthermore, manufacturers are embracing efforts to streamline technology and logistics for the provision of therapies at accessible prices.

Moreover, lack of manufacturing capabilities to meet growing consumer demand coupled with the resource and budget constraints faced by advanced therapy medicinal product developers has created lucrative avenues for contract services providers and has intensified the market competition. This has led to a rise in market activities by contract service providers. For instance, in November 2019, Fujifilm Diosynth established a 60,000-square-feet Gene Therapy Innovation Center to offer downstream, upstream, and analytical services.

Further key findings from the report suggest:

  • Cell therapies dominated the ATMP market in 2019, owing to the presence of a substantially high number of approved products for clinical use
  • Huge investments by commercial and non-commercial sponsors in the testing of cell-based product candidates in clinical studies has also spurred the revenue share of cell therapies
  • Stem cell-based therapies accounted for the major revenue share in 2019, owing to the high adoption of hematopoietic stem cell transplantation for the treatment of immune system and blood disorders
  • The recent FDA approval of Zolgensma gene therapy product in May 2019 has accelerated R&D activities in the gene therapy arena, this is anticipated to drive the segment growth at lucrative pace
  • Similarly, CAR-T therapy is projected to expand at a significant CAGR during the forecast period, resulted by the approval such as Kymriah and Yescarta in the past years
  • With a high number of approvals of therapies, North America, particularly U.S., captured the largest revenue share in 2019. Increasing marketing operations to sustain the growing market competition coupled with the presence of a relatively high number of candidates in the pipeline is anticipated to propel the U.S. market at a lucrative CAGR in the forthcoming years
  • Spark Therapeutics, Inc.; Bluebird Bio, Inc.; Novartis AG; Celgene Corporation; and Gilead Lifesciences, Inc. are some major revenue-generating companies operating in the advanced therapy medicinal product market
  • High prices of existing products and technological advancements in genetic tools have driven the entry of new players in the market

Table of content

Chapter 1 Executive Summary

  • 1.1 Market Outlook
  • 1.2 Competitive Milieu
  • 1.3 Segment Outlook
  • 1.4 Market Snapshot

Chapter 2 Research Methodology

  • 2.1 Information Procurement
  • 2.2 Information or Data Analysis
  • 2.3 Market Formulation & Validation
  • 2.4 Market Scope & Definition
    • 2.4.1 ATMP's definition as per the EU regulatory body:
    • 2.4.2 ATMP's definition as per the U.S. FDA:
  • 2.5 Market Model
    • 2.5.1 Historic and base year estimates
    • 2.5.2 Forecast analysis
      • 2.5.2.1 Case study
      • 2.5.2.1.1 MACI (Vericel Corporation):
      • 2.5.2.1.2 LAVIV (Azficel-T) (Fibrocell Technologies)

Chapter 3 Advanced Therapy Medicinal Products (ATMP) Market Variables, Trends, & Scope

  • 3.1 Advanced Therapy Medicinal Products (ATMP) Market Dynamics
    • 3.1.1 Market driver analysis
      • 3.1.1.1 Benefits over conventional therapies
      • 3.1.1.2 Growing competition among market players
      • 3.1.1.3 Increase in number of clinical trials for ATMP production
    • 3.1.2 Market restraints analysis
      • 3.1.2.1 Uncertainty on magnitude and duration of effect size of the new therapy
      • 3.1.2.2 Affordability and financial sustainability of therapies
    • 3.1.3 Market opportunity analysis
      • 3.1.3.1 Increasing financing in gene and cell therapy globally
      • 3.1.3.2 Facility expansion for cell and gene therapies
    • 3.1.4 Market challenge analysis
      • 3.1.4.1 Challenges in developing generics/biosimilar market for ATMPs
      • 3.1.4.2 Current challenges of on-market gene therapies
  • 3.2 Regulatory Landscape, by Geography
    • 3.2.1 U.S.
    • 3.2.2 Europe
    • 3.2.3 China
    • 3.2.4 Japan
  • 3.3 Payment & Pricing Models
    • 3.3.1 Payment models for innovative therapies
  • 3.4 Patent Landscape
  • 3.5 Deals, Funding's, Partnerships and Collaborations
    • 3.5.1 Merger & acquisition deals
    • 3.5.2 Collaboration & partnerships
  • 3.6 Pipeline Analysis
    • 3.6.1 Gene therapies
    • 3.6.2 Cell therapies
    • 3.6.3 NK cell therapies
    • 3.6.4 CAR-T therapies
    • 3.6.5 Tissue engineered products
  • 3.7 Advanced Therapy Medicinal Products (ATMP) Market-SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
  • 3.8 Industry Analysis - Porter's

Chapter 4 Advanced Therapy Medicinal Products (ATMP) Market: Therapy Class Estimates & Trend Analysis

  • 4.1 Advanced Therapy Medicinal Products (ATMP) Market: Therapy Class Movement Analysis
  • 4.2 Cell Therapy
    • 4.2.1 Global cell therapy market, 2015 - 2026 (USD Million)
    • 4.2.2 Stem cell therapy
      • 4.2.2.1 Global stem cell therapy market, 2015 - 2026 (USD Million)
    • 4.2.3 Non-stem cell therapy
      • 4.2.3.1 Global non-stem cell therapy market, 2015 - 2026 (USD Million)
  • 4.3 Gene Therapy
    • 4.3.1 Global gene therapy market, 2015 - 2026 (USD Million)
  • 4.4 CAR-T Therapy
    • 4.4.1 Global CAR-T therapy market, 2015 - 2026 (USD Million)
  • 4.5 Tissue Engineered Products
    • 4.5.1 Global tissue engineered products market, 2015 - 2026 (USD Million)

Chapter 5 Advanced Therapy Medicinal Products (ATMP) Market Categorization: Regional Estimates & Trend Analysis, by Therapy Type

  • 5.1 North America
    • 5.1.1 North America Advanced Therapy Medicinal Products (ATMP) market, by therapy type, 2015 - 2026 (USD Million)
    • 5.1.2 U.S.
      • 5.1.2.1 U.S. Advanced Therapy Medicinal Products (ATMP) market, by therapy type, 2015 - 2026 (USD Million)
    • 5.1.3 Canada
      • 5.1.3.1 Canada Advanced Therapy Medicinal Products (ATMP) market, by therapy type, 2015 - 2026 (USD Million)
  • 5.2 Europe
    • 5.2.1 Europe Advanced Therapy Medicinal Products (ATMP) market, by therapy type, 2015 - 2026 (USD Million)
  • 5.3 Asia Pacific
    • 5.3.1 Asia Pacific Advanced Therapy Medicinal Products (ATMP) market, by therapy type, 2015 - 2026 (USD Million)
    • 5.3.2 Japan
      • 5.3.2.1 Japan Advanced Therapy Medicinal Products (ATMP) market, by therapy type, 2015 - 2026 (USD Million)
    • 5.3.3 China
      • 5.3.3.1 China Advanced Therapy Medicinal Products (ATMP) market, by therapy type, 2015 - 2026 (USD Million)
  • 5.4 Rest of World (RoW)
    • 5.4.1 RoW Advanced Therapy Medicinal Products (ATMP) market, by therapy type, 2015 - 2026 (USD Million)

Chapter 6 Advanced Therapy Medicinal Products (ATMP) Market: Competitive Landscape

  • 6.1 Strategy Framework
  • 6.2 Key Participants Categorization
  • 6.3 Company Profile
    • 6.3.1 Spark Therapeutics, Inc.
      • 6.3.1.1 Company overview
      • 6.3.1.2 Financial performance
      • 6.3.1.3 Product benchmarking
      • 6.3.1.4 Strategic initiatives
    • 6.3.2 Bluebird Bio, Inc.
      • 6.3.2.1 Company overview
      • 6.3.2.2 Financial performance
      • 6.3.2.3 Product benchmarking
      • 6.3.2.4 Strategic initiatives
    • 6.3.3 Novartis AG
      • 6.3.3.1 Company overview
      • 6.3.3.1.1 AveXis, Inc.
      • 6.3.3.2 Financial performance (Novartis AG)
      • 6.3.3.2.1 Financial performance (AveXis, Inc.)
      • 6.3.3.3 Product benchmarking
      • 6.3.3.4 Strategic initiatives (Novartis AG)
      • 6.3.3.4.1 Strategic initiatives (AveXis, Inc.)
    • 6.3.4 UniQure N.V.
      • 6.3.4.1 Company overview
      • 6.3.4.2 Financial performance
      • 6.3.4.3 Product benchmarking
      • 6.3.4.4 Strategic initiatives
    • 6.3.5 Celgene Corporation
      • 6.3.5.1 Company overview
      • 6.3.5.2 Financial performance
      • 6.3.5.3 Product benchmarking
      • 6.3.5.4 Strategic initiatives
    • 6.3.6 Gilead Lifesciences, Inc.
      • 6.3.6.1 Company Overview
      • 6.3.6.2 Financial Performance
      • 6.3.6.3 Product Benchmarking
      • 6.3.6.4 Strategic initiatives
    • 6.3.7 Kolon TissueGene, Inc.
      • 6.3.7.1 Company overview
      • 6.3.7.2 Financial performance
      • 6.3.7.3 Product benchmarking
      • 6.3.7.4 Strategic initiatives
    • 6.3.8 JCR Pharmaceuticals Co., Ltd.
      • 6.3.8.1 Company overview
      • 6.3.8.2 Financial performance
      • 6.3.8.3 Product benchmarking
      • 6.3.8.4 Strategic initiatives
    • 6.3.9 MEDIPOST
      • 6.3.9.1 Company overview
      • 6.3.9.2 Financial performance
      • 6.3.9.3 Product benchmarking
      • 6.3.9.4 Strategic initiatives
    • 6.3.10 Vericel Corporation
      • 6.3.10.1 Company overview
      • 6.3.10.2 Financial performance
      • 6.3.10.3 Product benchmarking
      • 6.3.10.4 Strategic initiatives
    • 6.3.11 PHARMICELL Co., Ltd
      • 6.3.11.1 Company overview
      • 6.3.11.2 Product benchmarking
      • 6.3.11.3 Strategic initiatives
    • 6.3.12 Organogenesis Inc.
      • 6.3.12.1 Company overview
      • 6.3.12.2 Financial performance
      • 6.3.12.3 Product benchmarking
      • 6.3.12.4 Strategic initiatives

List of Tables

  • TABLE 1 Approved therapies that are considered in the revenue modeling
  • TABLE 2 Gene therapy buyouts and associated premiums
  • TABLE 3 Suggested payment models for innovative therapies
  • TABLE 4 Pipeline analysis: Cell therapy
  • TABLE 5 Pipeline analysis: Gene therapy
  • TABLE 6 Pipeline analysis: CAR T therapy
  • TABLE 7 Pipeline analysis: NK cell therapy
  • TABLE 8 Pipeline analysis: Tissue engineered products
  • TABLE 9 North America Advanced Therapy Medicinal Products (ATMP) market estimates & forecasts, by therapy type, 2015 - 2026 (USD Million)
  • TABLE 10 North America cell therapy market estimates & forecasts, by cell type, 2015 - 2026 (USD Million)
  • TABLE 11 U.S. Advanced Therapy Medicinal Products (ATMP) market estimates & forecasts, by therapy type, 2015 - 2026 (USD Million)
  • TABLE 12 U.S. cell therapy market estimates & forecasts, by cell type, 2015 - 2026 (USD Million)
  • TABLE 13 Canada Advanced Therapy Medicinal Products (ATMP) market estimates & forecasts, by therapy type, 2015 - 2026 (USD Million)
  • TABLE 14 Canada cell therapy market estimates & forecasts, by cell type, 2015 - 2026 (USD Million)
  • TABLE 15 Europe Advanced Therapy Medicinal Products (ATMP) market estimates & forecasts, by therapy type, 2015 - 2026 (USD Million)
  • TABLE 16 Europe cell therapy market estimates & forecasts, by cell type, 2015 - 2026 (USD Million)
  • TABLE 17 Asia Pacific Advanced Therapy Medicinal Products (ATMP) market estimates & forecasts, by therapy type, 2015 - 2026 (USD Million)
  • TABLE 18 Asia Pacific cell therapy market estimates & forecasts, by cell type, 2015 - 2026 (USD Million)
  • TABLE 19 Collaborations between Japanese players and global (Mesenchymal Stem Cell) MSC biotechs:
  • TABLE 20 China Advanced Therapy Medicinal Products (ATMP) market estimates & forecasts, by therapy type, 2015 - 2026 (USD Million)
  • TABLE 21 China cell therapy market estimates & forecasts, by cell type, 2015 - 2026 (USD Million)
  • TABLE 22 RoW Advanced Therapy Medicinal Products (ATMP) market estimates & forecasts, by therapy type, 2015 - 2026 (USD Million)
  • TABLE 23 RoW cell therapy market estimates & forecasts, by cell type, 2015 - 2026 (USD Million)

List of Figures

  • FIG. 1 Key stakeholders constituting the ATMP ecosystem
  • FIG. 2 Classification of companies
  • FIG. 3 Market segmentation & scope
  • FIG. 4 Market summary
  • FIG. 5 Market research process
  • FIG. 6 Information procurement
  • FIG. 7 Primary research pattern
  • FIG. 8 Market research approaches
  • FIG. 9 Value-chain-based sizing & forecasting
  • FIG. 10 QFD modeling for market share assessment
  • FIG. 11 Definition of ATMP by EU Regulatory Body
  • FIG. 12 Definition of ATMP by the U.S. FDA
  • FIG. 13 Definition of ATMP by the U.S. FDA
  • FIG. 14 Commodity flow analysis for historic and base year estimates
  • FIG. 15 Commodity flow analysis for forecast study
  • FIG. 16 Initiatives by Vericel Corporation to sustain market and increase revenue for its ATMPs
  • FIG. 17 Market trends & outlook
  • FIG. 18 Market driver relevance analysis (Current & future impact)
  • FIG. 19 Conventional therapies versus ATMP Advanced Therapy Medicinal Products (ATMP)
  • FIG. 20 ATMPs' value to healthcare systems, patients, & society
  • FIG. 21 Key strategies by market players to drive success in gene therapy arena
  • FIG. 22 Number of ongoing clinical trials, 2017 & 2018
  • FIG. 23 Some major industry sponsors of CAR T cell clinical trials, as of September 2019
  • FIG. 24 Distribution of the sponsors of ATMP clinical trials, 2016
  • FIG. 25 Distribution of the non-commercial sponsors of ATMP clinical trials
  • FIG. 26 Market restraints relevance analysis (Current & future impact)
  • FIG. 27 Uncertainties identified in this field with respect to magnitude and effect duration
  • FIG. 28 Market opportunity relevance analysis (Current & future impact)
  • FIG. 29 Global financings for ATMPs
  • FIG. 30 Recent and ongoing manufacturing capacity expansions for viral vector and large-scale cell therapies, as of 2017
  • FIG. 31 Market challenge relevance analysis (Current & future impact)
  • FIG. 32 Challenges & potential solutions
  • FIG. 33 Challenges in gene therapy arena by degree of difficulty to overcome
  • FIG. 34 Number of gene and cell therapy patents, 2003-2017
  • FIG. 35 CAR T-cell patent landscape by Derwent World Patents Index (DWPI)
  • FIG. 36 Major leaders in CAR T-cell therapy patent, by Derwent World Patents Index
  • FIG. 37 CAR T-Cell patent landscape by Derwent World Patents Index (DWPI)
  • FIG. 38 Patents for CAR T-cell therapy, 2016-2019
  • FIG. 39 Total M&A transactions values in cell therapy, gene therapy, & tissue engineered products, by year
  • FIG. 40 SWOT analysis, by factor (Political & legal, economic, and technological)
  • FIG. 41 Porter's Five Forces Analysis
  • FIG. 42 Advanced Therapy Medicinal Products (ATMP) market: Therapy class outlook key takeaways
  • FIG. 43 Global Advanced Therapy Medicinal Products (ATMP) market: Therapy class movement analysis
  • FIG. 44 Cell therapy clinical trials, 2018
  • FIG. 45 Global financings in cell therapy, 2016-2018
  • FIG. 46 Global cell therapy market, 2015 - 2026 (USD Million)
  • FIG. 47 Global stem cell therapy market, 2015 - 2026 (USD Million)
  • FIG. 48 Global non-stem cell therapy market, 2015 - 2026 (USD Million)
  • FIG. 49 Volume of gene therapies in development, by companies; as of August 2018
  • FIG. 50 Global gene therapy market, 2015 - 2026 (USD Million)
  • FIG. 51 Top 10 players in the CAR T-cell therapy development field
  • FIG. 52 Annual investment in CAR-T space
  • FIG. 53 Number of CAR-T related publications from 2015 to 2018
  • FIG. 54 Global CAR-T therapy market, 2015 - 2026 (USD Million)
  • FIG. 55 Global tissue engineered products market, 2015 - 2026 (USD Million)
  • FIG. 56 Regional marketplace: Key takeaway
  • FIG. 57 Advanced Therapy Medicinal Products (ATMP) market regional outlook, 2019 & 2026
  • FIG. 58 North America Advanced Therapy Medicinal Products (ATMP) market, 2015 - 2026 (USD Million)
  • FIG. 59 U.S. Advanced Therapy Medicinal Products (ATMP) market, 2015 - 2026 (USD Million)
  • FIG. 60 Canada Advanced Therapy Medicinal Products (ATMP) market, 2015 - 2026 (USD Million)
  • FIG. 61 Registered cell therapy contract manufacturing organization (CMO) locations in the EU
  • FIG. 62 Europe Advanced Therapy Medicinal Products (ATMP) market, 2015 - 2026 (USD Million)
  • FIG. 63 Drivers for rapid growth of cell therapy in Asia
  • FIG. 64 Asia Pacific Advanced Therapy Medicinal Products (ATMP) market, 2015 - 2026 (USD Million)
  • FIG. 65 Japan Advanced Therapy Medicinal Products (ATMP) market, 2015 - 2026 (USD Million)
  • FIG. 66 China Advanced Therapy Medicinal Products (ATMP) market, 2015 - 2026 (USD Million)
  • FIG. 67 RoW Advanced Therapy Medicinal Products (ATMP) market, 2015 - 2026 (USD Million)
  • FIG. 68 Strategy framework
  • FIG. 69 Key participants categorization